Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

April 30, 2024

Eton Pharmaceuticals submits New Drug Application to FDA for ET-400 (hydrocortisone oral solution), expecting a 10-month review for potential approval in Q1 2025.

Highlighted Terms

hydrocortisone Eton Pharmaceuticals Hydrocortisone Oral Solution Adrenocortical Insufficiency ET-400 FDA U.S. Food and Drug Administration U.S. Patent and Trademark Office

Related News

drugs.com

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals submits New Drug Application to FDA for ET-400 (hydrocortisone oral solution), expecting a 10-month review for potential approval in Q1 2025.